Nightstar Therapeutics PLC Sponsored ADR (NASDAQ:NITE) – Jefferies Group issued their Q3 2017 earnings estimates for Nightstar Therapeutics PLC Sponsored ADR in a research note issued on Monday. Jefferies Group analyst M. Yee expects that the company will earn ($0.19) per share for the quarter. Jefferies Group has a “Buy” rating and a $25.00 price target on the stock. Jefferies Group also issued estimates for Nightstar Therapeutics PLC Sponsored ADR’s Q4 2017 earnings at ($0.16) EPS, FY2017 earnings at ($0.67) EPS, FY2018 earnings at ($1.34) EPS, FY2019 earnings at ($1.45) EPS and FY2020 earnings at ($1.80) EPS.

COPYRIGHT VIOLATION WARNING: “Nightstar Therapeutics PLC Sponsored ADR to Post Q3 2017 Earnings of ($0.19) Per Share, Jefferies Group Forecasts (NITE)” was originally published by American Banking News and is the property of of American Banking News. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/25/nightstar-therapeutics-plc-sponsored-adr-to-post-q3-2017-earnings-of-0-19-per-share-jefferies-group-forecasts-nite.html.

Other equities research analysts have also recently issued research reports about the stock. Wedbush began coverage on shares of Nightstar Therapeutics PLC Sponsored ADR in a research report on Monday. They set an “outperform” rating and a $19.00 price target for the company. Leerink Swann assumed coverage on shares of Nightstar Therapeutics PLC Sponsored ADR in a report on Monday. They set an “outperform” rating and a $25.00 price objective for the company. Finally, BMO Capital Markets assumed coverage on shares of Nightstar Therapeutics PLC Sponsored ADR in a report on Monday. They set an “outperform” rating and a $30.00 price objective for the company.

Nightstar Therapeutics PLC Sponsored ADR (NASDAQ NITE) opened at 18.77 on Wednesday. Nightstar Therapeutics PLC Sponsored ADR has a 52-week low of $14.56 and a 52-week high of $24.93. The firm has a 50-day moving average of $18.94 and a 200 day moving average of $18.94. The company’s market cap is $527.46 million.

A hedge fund recently bought a new stake in Nightstar Therapeutics PLC Sponsored ADR stock. Nationwide Fund Advisors acquired a new position in shares of Nightstar Therapeutics PLC Sponsored ADR (NASDAQ:NITE) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 62,300 shares of the company’s stock, valued at approximately $1,196,000. Nationwide Fund Advisors owned 0.22% of Nightstar Therapeutics PLC Sponsored ADR as of its most recent SEC filing.

About Nightstar Therapeutics PLC Sponsored ADR

Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases.

Receive News & Ratings for Nightstar Therapeutics PLC Sponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics PLC Sponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.